NIKKEI 225
38,615.38 -331.55 (-0.85%) HANG SENG
19,287.06 +66.44 (+0.35%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,416.50 -9.40 (-0.39%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
54,899.90 -943.21 (-1.69%)
EGRX May 2024 5.000 put
| Previous close | 0.6300 |
| Open | 0.3000 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.3000 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 64 |
GlobeNewswireEagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting
Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025WOODCLIFF LAKE, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting (PONV) in pediatric patients from birth (full-term) until 17 years of age at the upcomi
- GlobeNewswire
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
-- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versus placebo --WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the sustained response of amisulpride for the rescue treatment of postoperative nausea
- GlobeNewswire
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”), with the Securities and Exchange Commission (the “SEC”), the
